Genentech, Inc.
NEWS
Genentech said the Phase III combination therapy improved progression-free survival by 26 percent in mRCC patients whose disease expressed a PD-L1 protein.
2017 was the second-best year for FDA approvals since 1996.
The fact that Roche has separate R&D units has been the topic of second-guessing on the part of observers and analysts.
A little less than two years after tying up a multi-billion deal with Sanofi, DiCE Molecules scored another collaborative deal.
A look at the latest batch of FDA approvals this year.
A look at what three ex-Genentech employees have accomplished at Denali so far.
A look at some of the exciting data clinicians and investors got to feast on from ASH.
At the ASH meeting in Atlanta this morning, AbbVie and Genentech unveiled stellar results of its Phase III combination trial of Venclexta and Rituxan to treat patients with relapsed or refractory CLL.
One of the most important points about Hemlibra’s approval, beyond its significant efficacy is the positive impact it will have one the quality of life for these hemophilia patients.
JOBS
IN THE PRESS